Re: Tamás Fazekas, Marcin Miszczyk, Alexander Giesen, et al. Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.006
Re: Tamás Fazekas, Marcin Miszczyk, Alexander Giesen, et al. Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.006. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456925002603?dgcid=rss_sd_all
Re: Tamás Fazekas, Marcin Miszczyk, Alexander Giesen, et al. Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.006. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456925002603?dgcid=rss_sd_all
“Re: Tamás Fazekas, Marcin Miszczyk, Alexander Giesen, et al. Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.006.” European Urology Focus.
@article{article45502,
title = {Re: Tamás Fazekas, Marcin Miszczyk, Alexander Giesen, et al. Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.006},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456925002603?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...